BioVaxys Technology Corp. is developing its patented DPX™ platform to address the challenges of lipid nanoparticles (LNPs) in mRNA vaccine delivery. Learn how DPX improves stability, immune responses, and manufacturing economics as the mRNA vaccine market projects $48 billion growth by 2030.
Browsing: Featured Company
Used for company news we create.
GivBux (OTC: GBUX), a publicly traded super app and charitable giving platform, is creating a sharing economic community of brands. The app provides consumers with an easier and more convenient way to shop and buy, as well as merchants a more efficient and profitable way to advertise.
BioVaxys Secures GMP-Grade Lipid Supply for Production of DPX-Based Vaccines in Advance of Preclinical and Clinical Program Ramp-Up VANCOUVER, BCDecember…
BioVaxys Shares New Data on its DPX™ Immune Educating Platform at Personalized Cancer Vaccine Summit DPX Formulations Superior to Mixing…
Saguenay, QuebecDecember 2, 2024First Phosphate Corp. (CSE: PHOS) (OTCQB: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company”) is pleased to…
MADISON, WINovember 20th, 2024 BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys”) and SpayVac for Wildlife, Inc. are…
BioVaxys to Participate in the US Government Biomedical Advanced Research and Development Authority (BARDA) Rapid Response Partnership Vehicle (RRPV) Vaccine…
Study [KK1] Results Position Company to Target Segments of $270B+ Multi-Billion Dollar Drug Delivery Systems Market1 VANCOUVER, BC, October 31st, 2024…
In the ever-evolving world of business, scaling and making a strategic market exit has become a challenging endeavor. For entrepreneurs…
In a time when global climate commitments are becoming more critical, XGC Software is emerging as a thought leader in…